Modern cancer treatment has entered a new era thanks to immunotherapy.
Instead of directly attacking cancer cells with chemicals or radiation, immunotherapy encourages the immune system to do the job itself. This approach has helped many patients live longer and has changed the outlook for several types of cancer.
One of the most widely used forms of immunotherapy involves drugs called immune checkpoint inhibitors. These medicines remove some of the natural brakes that normally keep the immune system under control.
Once these brakes are released, immune cells can attack cancer more effectively. However, the same powerful immune response can sometimes cause unintended problems.
In certain patients, the immune system begins attacking healthy tissues as well as tumors. The heart and blood vessels can become inflamed, creating potentially dangerous complications. Doctors face a difficult challenge because stopping treatment may protect the heart but could also allow the cancer to grow again.
A new study presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting may offer a solution. Researchers led by Dr. Jaume Otaegui at Washington University in St. Louis developed a novel imaging strategy that can simultaneously monitor tumor activity and inflammation affecting the cardiovascular system.
The key to the new approach is a protein known as CCR2. Scientists have learned that CCR2 appears in inflammatory cells found within both tumors and diseased blood vessels. Because of this dual role, CCR2 provides a unique opportunity to track two important health problems with a single imaging technique.
To visualize CCR2, the research team used a PET imaging tracer called 64Cu-DOTA-ECL1i. PET imaging works by injecting tiny amounts of specially designed tracers into the body.
These tracers attach to specific biological targets and create signals that can be detected by scanning equipment. The result is a detailed picture of disease activity that cannot be seen with ordinary imaging methods.
The researchers tested their method in mice that had both oral cancer and atherosclerosis. Atherosclerosis is a condition in which fatty deposits and inflammation build up inside arteries, increasing the risk of heart attacks and strokes. This model allowed the scientists to study cancer treatment and cardiovascular inflammation at the same time.
During the experiment, some mice received immune checkpoint inhibitor therapy. Others received additional treatment with itacitinib, a drug designed to reduce inflammatory activity. The researchers then used PET scans to evaluate what was happening throughout the body.
The scans revealed that the new CCR2 imaging method was more effective than standard FDG PET imaging at highlighting both tumors and inflammatory artery plaques. This allowed researchers to see changes more clearly and track the effects of treatment with greater precision.
The results provided several important insights. Immune checkpoint inhibitor therapy slowed the growth of tumors, confirming its effectiveness as a cancer treatment.
However, it also increased inflammation-related signals in the cardiovascular system. This finding suggests that while the therapy was helping fight cancer, it was also creating conditions that could potentially increase heart-related risks.
The most encouraging result came from the combination therapy group. When itacitinib was added to the cancer treatment, tumors responded even better while cardiovascular inflammation decreased. The scans showed lower CCR2 activity and fewer inflammatory cells within the arteries.
This dual benefit is particularly significant because cancer doctors often struggle to balance treatment effectiveness against side effects. A strategy that improves tumor control while protecting the cardiovascular system would represent a major advance in patient care.
The study also highlights the growing role of molecular imaging in modern medicine. Instead of relying solely on symptoms or routine tests, doctors may soon be able to detect harmful biological changes much earlier. This could allow them to intervene before severe complications develop.
Because the imaging tracer used in this study is already undergoing clinical evaluation, the path toward human use may be shorter than for entirely new technologies. Nevertheless, researchers emphasize that more work is needed, especially to confirm whether the combination therapy produces similar benefits in patients.
Looking critically at the findings, the study’s greatest strength is its ability to connect cancer treatment and cardiovascular health within a single monitoring system. The research suggests that future cancer care could become much more personalized, allowing doctors to identify risks early and adjust treatments accordingly.
However, since the work was performed in animal models, human studies remain essential before firm conclusions can be drawn. Even with this limitation, the results provide compelling evidence that advanced imaging and targeted anti-inflammatory therapies may help make immunotherapy both safer and more effective in the years ahead.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Source: Washington University in St. Louis.
